Citadel Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $482M | Buy |
2,217,000
+183,200
| +9% | +$40.6M | 0.08% | 183 |
|
|
2025
Q4 | $465M | Sell |
2,033,800
-375,300
| -16% | -$85.5M | 0.07% | 206 |
|
|
2025
Q3 | $558M | Buy |
2,409,100
+155,200
| +7% | +$31.6M | 0.08% | 155 |
|
|
2025
Q2 | $418M | Sell |
2,253,900
-369,200
| -14% | -$68.6M | 0.07% | 192 |
|
|
2025
Q1 | $550M | Buy |
2,623,100
+680,800
| +35% | +$132M | 0.1% | 112 |
|
|
2024
Q4 | $345M | Sell |
1,942,300
-525,200
| -21% | -$96.6M | 0.06% | 229 |
|
|
2024
Q3 | $487M | Sell |
2,467,500
-150,300
| -6% | -$28.1M | 0.09% | 140 |
|
|
2024
Q2 | $449M | Buy |
2,617,800
+108,900
| +4% | +$18M | 0.09% | 141 |
|
|
2024
Q1 | $457M | Sell |
2,508,900
-2,816,000
| -53% | -$485M | 0.09% | 147 |
|
|
2023
Q4 | $825M | Buy |
5,324,900
+1,504,200
| +39% | +$219M | 0.16% | 61 |
|
|
2023
Q3 | $570M | Buy |
3,820,700
+1,298,100
| +51% | +$191M | 0.12% | 85 |
|
|
2023
Q2 | $340M | Sell |
2,522,600
-468,500
| -16% | -$68.7M | 0.07% | 152 |
|
|
2023
Q1 | $477M | Buy |
2,991,100
+156,400
| +6% | +$23.9M | 0.1% | 99 |
|
|
2022
Q4 | $458M | Sell |
2,834,700
-868,900
| -23% | -$133M | 0.11% | 122 |
|
|
2022
Q3 | $497M | Buy |
3,703,600
+242,000
| +7% | +$34.7M | 0.11% | 92 |
|
|
2022
Q2 | $530M | Buy |
3,461,600
+676,000
| +24% | +$103M | 0.14% | 83 |
|
|
2022
Q1 | $452M | Buy |
2,785,600
+588,202
| +27% | +$85.4M | 0.09% | 125 |
|
|
2021
Q4 | $298M | Sell |
2,197,398
-149,114
| -6% | -$17.6M | 0.06% | 216 |
|
|
2021
Q3 | $253M | Buy |
2,346,512
+698,698
| +42% | +$79.8M | 0.05% | 265 |
|
|
2021
Q2 | $186M | Sell |
1,647,814
-137,270
| -8% | -$15.5M | 0.04% | 348 |
|
|
2021
Q1 | $193M | Sell |
1,785,084
-101,400
| -5% | -$10.8M | 0.05% | 301 |
|
|
2020
Q4 | $202M | Sell |
1,886,484
-85,616
| -4% | -$8.23M | 0.05% | 259 |
|
|
2020
Q3 | $173M | Sell |
1,972,100
-704,100
| -26% | -$66.3M | 0.05% | 242 |
|
|
2020
Q2 | $263M | Sell |
2,676,200
-314,800
| -11% | -$27.7M | 0.09% | 115 |
|
|
2020
Q1 | $228M | Buy |
2,991,000
+170,900
| +6% | +$14.6M | 0.1% | 113 |
|
|
2019
Q4 | $250M | Sell |
2,820,100
-715,000
| -20% | -$59.4M | 0.11% | 130 |
|
|
2019
Q3 | $268M | Sell |
3,535,100
-56,800
| -2% | -$3.89M | 0.13% | 104 |
|
|
2019
Q2 | $261M | Buy |
3,591,900
+1,452,700
| +68% | +$114M | 0.12% | 106 |
|
|
2019
Q1 | $172M | Buy |
2,139,200
+604,100
| +39% | +$49.4M | 0.09% | 181 |
|
|
2018
Q4 | $142M | Buy |
1,535,100
+113,200
| +8% | +$9.95M | 0.08% | 214 |
|
|
2018
Q3 | $134M | Buy |
1,421,900
+168,700
| +13% | +$16M | 0.06% | 306 |
|
|
2018
Q2 | $116M | Buy |
1,253,200
+501,400
| +67% | +$49M | 0.06% | 317 |
|
|
2018
Q1 | $71.2M | Buy |
751,800
+59,200
| +9% | +$6.5M | 0.04% | 440 |
|
|
2017
Q4 | $67M | Sell |
692,600
-118,500
| -15% | -$11.2M | 0.04% | 487 |
|
|
2017
Q3 | $72.1M | Buy |
811,100
+230,900
| +40% | +$17.6M | 0.06% | 372 |
|
|
2017
Q2 | $42.1M | Sell |
580,200
-181,400
| -24% | -$12.2M | 0.04% | 580 |
|
|
2017
Q1 | $49.6M | Sell |
761,600
-58,100
| -7% | -$3.65M | 0.05% | 457 |
|
|
2016
Q4 | $51.3M | Buy |
819,700
+533,900
| +187% | +$32.6M | 0.05% | 375 |
|
|
2016
Q3 | $18M | Sell |
285,800
-58,700
| -17% | -$3.8M | 0.02% | 925 |
|
|
2016
Q2 | $21.3M | Sell |
344,500
-99,500
| -22% | -$6.06M | 0.02% | 742 |
|
|
2016
Q1 | $25.4M | Buy |
444,000
+118,500
| +36% | +$6.6M | 0.03% | 612 |
|
|
2015
Q4 | $19.3M | Sell |
325,500
-87,200
| -21% | -$5.02M | 0.02% | 864 |
|
|
2015
Q3 | $22.5M | Sell |
412,700
-28,800
| -7% | -$1.87M | 0.02% | 822 |
|
|
2015
Q2 | $29.7M | Buy |
441,500
+192,700
| +77% | +$12.6M | 0.03% | 772 |
|
|
2015
Q1 | $14.6M | Buy |
248,800
+105,000
| +73% | +$6.34M | 0.01% | 1173 |
|
|
2014
Q4 | $9.41M | Sell |
143,800
-49,200
| -25% | -$3.1M | 0.01% | 1445 |
|
|
2014
Q3 | $11.1M | Buy |
193,000
+60,500
| +46% | +$3.36M | 0.01% | 1285 |
|
|
2014
Q2 | $7.48M | Sell |
132,500
-52,400
| -28% | -$2.75M | 0.01% | 1496 |
|
|
2014
Q1 | $9.5M | Buy |
184,900
+58,200
| +46% | +$2.94M | 0.01% | 1303 |
|
|
2013
Q4 | $6.69M | Buy |
126,700
+78,000
| +160% | +$3.83M | 0.01% | 1484 |
|
|
2013
Q3 | $2.18M | Sell |
48,700
-20,100
| -29% | -$891K | ﹤0.01% | 2337 |
|
|
2013
Q2 | $2.84M | Buy |
+68,800
| New | +$3.01M | ﹤0.01% | 2111 |
|
Other funds holding ABBV
VCM
VPM
Citadel Advisors's ABBV Position: Q1 2026 in Review
Citadel Advisors reduced its AbbVie (ABBV) stake by 33% in Q1 2026, selling an estimated $53.9M and leaving 490,285 shares worth $107M. The position accounts for 0.02% of the portfolio, ranked #768.
Citadel Advisors first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $719M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Citadel Advisors held 490,285 shares of AbbVie worth $107M as of Q1 2026.
- Citadel Advisors sold 243,066 AbbVie shares in Q1 2026, an estimated $53.9M.
- AbbVie made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #768 holding.
- Citadel Advisors first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
- Citadel Advisors's AbbVie position peaked at $719M in Q3 2025.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.